KYBELLA (deoxycholic acid)
AESTHETIC AGENTS FOR SUBCUTANEOUS ADIPOSE LYSIS · EXCESS SUBMENTAL FAT
KYTHERA BIOPHAR
Drug class
Aesthetic Agents for Subcutaneous Adipose Lysis
Aesthetic agents for subcutaneous adipose lysis—predominantly classified by regulatory and clinical reference bodies as injectable cytolytic agents—are pharmacological treatments designed for non-surgical reduction of localized adipose tissue. Read more about Aesthetic Agents for Subcutaneous Adipose Lysis
2 drugs in this class 2 manufacturers
Drugs in Aesthetic Agents for Subcutaneous Adipose Lysis
QWO (collagenase Clostridium histolyticum-aaes)
COLLAGENASE ENZYMES, INJECTABLE · MODERATE TO SEVERE CELLULITE OF THE BUTTOCKS IN WOMEN
ENDO AESTHETICS
Filter & compare in the drug finder →
Opens the drug finder with Aesthetic Agents for Subcutaneous Adipose Lysis preselected. Add indication or manufacturer filters there.
Aesthetic agents for subcutaneous adipose lysis—predominantly classified by regulatory and clinical reference bodies as injectable cytolytic agents—are pharmacological treatments designed for non-surgical reduction of localized adipose tissue.
These agents, exemplified by synthetic deoxycholic acid, function as biological surfactants that physically disrupt the phospholipid bilayer of adipocyte cell membranes upon subcutaneous injection, causing irreversible cell lysis followed by macrophage-mediated clearance of cellular debris and targeted volume loss.
Their primary established clinical indication in aesthetic medicine is the improvement of moderate to severe convex contouring and fullness associated with submental subcutaneous fat in adults.
Regulatory authorities such as the Food and Drug Administration do not recognize this grouping as a generalized systemic therapy for obesity or metabolic disease, and use outside well-defined localized anatomic regions remains strictly off-label or unapproved due to potential tissue damage.
-
medlineplus.gov
Aesthetic agents for subcutaneous adipose lysis—predominantly classified by regulatory and clinical reference bodies as injectable cytolytic agents—are pharmacological treatments designed for non-surgical reduction of localized adipose tissue Their primary established clinical indication in aesthetic medicine is the improvement of moderate to severe convex contouring and fullness associated with submental subcutaneous fat in adults
-
drugbank.com
Aesthetic agents for subcutaneous adipose lysis—predominantly classified by regulatory and clinical reference bodies as injectable cytolytic agents—are pharmacological treatments designed for non-surgical reduction of localized adipose tissue These agents, exemplified by synthetic deoxycholic acid, function as biological surfactants that physically disrupt the phospholipid bilayer of adipocyte cell membranes upon subcutaneous injection, causing irreversible cell lysis followed by macrophage-medi...
-
frontiersin.org
These agents, exemplified by synthetic deoxycholic acid, function as biological surfactants that physically disrupt the phospholipid bilayer of adipocyte cell membranes upon subcutaneous injection, causing irreversible cell lysis followed by macrophage-mediated clearance of cellular debris and targeted volume loss
-
fda.gov
These agents, exemplified by synthetic deoxycholic acid, function as biological surfactants that physically disrupt the phospholipid bilayer of adipocyte cell membranes upon subcutaneous injection, causing irreversible cell lysis followed by macrophage-mediated clearance of cellular debris and targeted volume loss Their primary established clinical indication in aesthetic medicine is the improvement of moderate to severe convex contouring and fullness associated with submental subcutaneous fat i...
-
fda.gov
Regulatory authorities such as the Food and Drug Administration do not recognize this grouping as a generalized systemic therapy for obesity or metabolic disease, and use outside well-defined localized anatomic regions remains strictly off-label or unapproved due to potential tissue damage
-
fda.gov
Regulatory authorities such as the Food and Drug Administration do not recognize this grouping as a generalized systemic therapy for obesity or metabolic disease, and use outside well-defined localized anatomic regions remains strictly off-label or unapproved due to potential tissue damage
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.